Company news

Ascentage Pharma Group International news in 2026

Ascentage Pharma Group International's news releases, calls and decks from 2026, newest first.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 5, 2026

Voluntary announcement - Ascentage Pharma to present data from multiple trials, including an oral presentation of APG-5918, at ASH annual meeting 2026

November 4, 2026

Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme

October 27, 2026

Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme

October 22, 2026

Voluntary announcement - Ascentage Pharma's Lisaftoclax granted breakthrough therapy designation in China for treatment-naive CLL/SLL

October 20, 2026

Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme

October 15, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

Voluntary announcement - acquisition of shares by the chairman and executive director

September 28, 2026

Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme

September 28, 2026

Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme

September 17, 2026

Interim report 2026

September 16, 2026

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

August 19, 2026

CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

August 5, 2026

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

August 5, 2026

Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer

August 2, 2026

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

July 26, 2026

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

June 14, 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

May 31, 2026

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

May 31, 2026

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

May 31, 2026

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

May 21, 2026

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

May 12, 2026

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

April 20, 2026

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

April 18, 2026

Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

March 25, 2026

Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026

March 16, 2026

Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026

March 11, 2026

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

February 23, 2026

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

February 9, 2026

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

February 5, 2026

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 14, 2026

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

January 6, 2026

Calls in 2026

Decks in 2026